From the beginning, Hims & Hers CEO Andrew Dudum had imagined he would take his startup public through a traditional IPO. But last month, the direct-to-consumer health startup ended up taking a different route. The startup merged with a special-purpose
Gaining insights into social factors affecting patients’ lives can be used to augment healthcare delivery in a big way. That’s according to Dr. Courtney Lyles, an associate professor at the University of California San Francisco, who helped create an expansive
Truvian Sciences plans to seek FDA clearance and CLIA certification for its benchtop blood testing device. Photo credit: Truvian Sciences Truvian Sciences, a startup building a benchtop blood analyzer, raised $105 million in funding. The San Diego-based company plans to
Like with so many different agencies under President Joe Biden, the Centers for Medicare and Medicaid Services will look wildly different in the next four years than how it did under his predecessor. Helming this change will likely be the
AppliedVR’s program includes a feature for users to go through guided breathing exercises, which are visualized in a 3-D nature scene. Photo credit: AppliedVR For the past six years, AppliedVR has been distributing VR headsets to hospitals to see if
Vividion Therapeutics has technology that finds ways to hit promising disease targets that were previously deemed “undruggable.” Now it has $135 million that might allow it to find something else: a public stock listing. The Series C round of
Innovaccer Inc.’s Series D funding round has propelled it to unicorn status. The healthcare technology company gained $105 million in its latest funding round, which pushed its valuation to $1.3 billion. The total investment in the company jumped to $225
Contract research organization ICON is set to acquire rival PRA Health Sciences in a $12 billion deal that will vault the combined company into second place among clinical trial services providers. The PRA acquisition deal is a combination of
MedCity News has assembled compelling speakers to address the Covid-prompted rapid transformation of healthcare at this year’s virtual INVEST conference, April 19-23. INVEST is a premier international healthcare investing event hosted in partnership with MHIN, a Midwest healthcare investor organization.
The next hurdles for gene-editing medicines are therapies that do their work inside the patient. But so far, biotechs have had a hard time developing such in vivo therapies that target anything other than the liver. Beam Therapeutics has